Although total HSP90 protein levels remained unchanged by HSP90 inhibition (in line with previous reports [33]), we demonstrated client protein knockdown at nanomolar doses of the pro-survival kinase AKT, which has been previously reported to mediate drug resistance and poor prognosis in AML [34]. The gene discussed is AKT1; the disease is acute myeloid leukemia.